FluoroPharma is Granted Patent Rights for BFPET in Australia, Expanding Global Patent Position

BOSTON, March 19, 2012 (GLOBE NEWSWIRE) -- FluoroPharma Medical, Inc. (OTCBB:FPMI) today announces that BFPET, its imaging agent for measuring cardiovascular blood flow, has been granted patent rights in Australia. BFPET is a unique imaging agent that, when used in conjunction with stress-testing, identifies patients with suspected and proven coronary artery disease (CAD). The patent expiration date is 2025.